

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
7 March 2002 (07.03.2002)

PCT

(10) International Publication Number  
**WO 02/18330 A1**

(51) International Patent Classification<sup>7</sup>: **C07C 311/51**,  
311/41, A61K 31/195

(21) International Application Number: PCT/US01/41910

(22) International Filing Date: 28 August 2001 (28.08.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/228,682 29 August 2000 (29.08.2000) US

(71) Applicant (for all designated States except US): **NOBEX CORPORATION** [US/US]; P.O. Box 13940, Research Triangle Park, NC 27709-3940 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **EKWURIBE, Nnochiri, N.** [NG/US]; 216 Coltsgate Drive, Cary, NC 27511 (US). **MALSON, Elizabeth** [US/US]; 222 N. Buena Vista Street, Apt. 103, Burbank, CA 91505 (US). **RIGGS-SAUTHIER, Jennifer** [US/US]; 3900 Knickerbocker Parkway, Apt. G, Raleigh, NC 27612 (US).

(74) Agent: **MYERS BIGEL SIBLEY & SAJOVEC**; P.O. Box 37428, Raleigh, NC 27627 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: 5-ASA DERIVATIVES HAVING ANTI-INFLAMMATORY AND ANTIBIOTIC ACTIVITY AND METHODS OF TREATING DISEASES THEREWITH

(57) Abstract: Compounds are disclosed represented by the following formula (I): where R<sup>1</sup> is a substituted or unsubstituted phenyl group, and where Z is selected such that a compound, Z-R<sup>1</sup>-NH<sub>2</sub>, formed by cleavage of the azo bond is a non-absorbable antibiotic; or an ester or pharmacologically acceptable salt of the compound of formula (I). Compounds of the present invention may be utilized for the prophylaxis or treatment of various diseases including, but not limited to, intestinal diseases such as inflammatory bowel disease and/or traveler's diarrhea, liver diseases such as hepatic encephalopathy, and/or diseases treatable by a non-absorbable antibiotic.

WO 02/18330 A1

**5-ASA DERIVATIVES HAVING ANTI-INFLAMMATORY  
AND ANTIBIOTIC ACTIVITY AND  
METHODS OF TREATING DISEASES THEREWITH**

**Related Application**

This application claims the benefit of United States Provisional Application Number 60/228,682, filed August 29, 2000, the disclosure of which is incorporated herein by reference in its entirety.

**Field of the Invention**

The present invention relates to 5-ASA derivatives and methods of treating diseases therewith.

**Background of the Invention**


Many people suffer from inflammatory bowel disease (IBD). IBD is a generic term used to refer to two inflammatory diseases, ulcerative colitis and Crohn's disease. Ulcerative colitis is a chronic inflammatory disease of unknown etiology that affects various portions of the gastrointestinal (GI) tract, particularly the lower GI tract, and more particularly the colon and/or rectum. Crohn's disease is a serious inflammatory disease of the GI tract. It predominates in the intestine (ileum) and the large intestine (colon). Various medications are being used to treat inflammatory bowel disease.

It is known to use mesalamine, 5-aminosalicylic acid (5-ASA) to treat ulcerative colitis. While mesalamine may be active in treating ulcerative colitis, it may be absorbed as it passes through the GI tract. This absorption may adversely

affect the amount of mesalamine that reaches the lower GI tract, particularly the colon and rectum.

Various mesalamine formulations have been introduced in an attempt to protect mesalamine as it passes through the gut and the upper GI tract. One such formulation is a delayed-release formulation that relies on a pH-sensitive coating surrounding the mesalamine. The coating allows the mesalamine to pass through the gut and upper GI tract without being absorbed so that the mesalamine reaches the target (i.e. the lower GI tract, particularly the colon and/or rectum) intact. In another formulation, mesalamine microspheres surround a mesalamine core. This formulation releases mesalamine throughout the GI tract, rather than targeting the colon specifically. It may be difficult to predict the bioavailability of the various mesalamine formulations when administered to a wide variety of individuals. As a result, it may be difficult to determine the proper dosage for a given individual.


It is also known to use sulfasalazine having the following formula to treat ulcerative colitis.



However, sulfasalazine is metabolized in the body to form mesalamine (5-aminosalicylic acid (5-ASA)) and sulfapyridine. Several adverse side effects have been noted from the use of sulfasalazine including nausea, vomiting, abdominal discomfort, and headache to name just a few. These adverse side effects are usually attributed to the activity of sulfapyridine in the GI tract, as well as that absorbed into the system.


U.S. Patent No. 4,412,992 to Chan proposes mesalamine derivatives. Unlike sulfasalazine, the breakdown of these compounds in the intestinal tract may not give rise to undesirable metabolic products. In fact, the non-mesalamine metabolic products may be innocuous.

It is also known to use olsalazine having the following formula to treat ulcerative colitis.




In addition to being relatively expensive to make, olsalazine may have adverse side effects including diarrhea.

- 5 It is also known to use azathioprine (6-(1-methyl-4-nitimidazol-5-ylthio)purine) in the treatment of inflammatory bowel disease. Azathioprine has the following chemical structure:




- 10 It is also known to use 6-mercaptopurine, a metabolite of azathioprine, to treat inflammatory bowel disease. 6-mercaptopurine has the following chemical structure:



Methotrexate (L-4-amino-N<sup>10</sup>-methylpteroyl-glutamic acid) has also been used to treat inflammatory bowel disease. Methotrexate has the following chemical

15 structure:




The polypeptide cyclosporine, which has traditionally been given to transplant patients to prevent organ rejection, has also been used to treat inflammatory bowel disease. The use of cyclosporine to treat IBD may be limited, however, by the various side effects associated with this medication. These side effects include high blood pressure, kidney damage, tremors, headaches, seizures, excessive hair growth, excessive gum growth, confusion, coma, and gout.

It is also known to use the absorbable antibiotics metronidazole and ciprofloxacin to treat inflammatory bowel disease.


### Summary of the Invention

According to embodiments of the present invention, compounds are provided having the structure of Formula I:




where  $R^1$  is a substituted or unsubstituted phenyl group, and where Z is selected such that a compound,  $Z-R^1-NH_2$ , formed by cleavage of the azo bond is a non-absorbable antibiotic. Preferably, the compound,  $Z-R^1-NH_2$ , is a metabolite formed by *in vivo* cleavage of the azo bond.  $R^1$  is preferably an unsubstituted phenyl group. When  $R^1$  is a substituted phenyl, it is preferably substituted with lower alkyl.


According to other embodiments of the present invention, compounds are provided having the structure of Formula II:




where X is  $\text{—SO}_2\text{—}$  or  $\text{—CO—}$  and Y is:



5



or



10 or the esters or pharmaceutically acceptable salts thereof.

Pharmaceutical compositions including compounds according to the present invention in admixture with a pharmaceutical diluent or carrier are also provided, as are methods of utilizing such compounds in the treatment or prophylaxis of various diseases including, but not limited to, inflammatory bowel disease.

15

### Brief Description of the Drawings

Figure 1 illustrates a synthesis route for compounds of the present invention.

Figure 2 illustrates a synthesis route for compounds of the present invention.

20

### Detailed Description of the Preferred Embodiments


The invention will now be described with respect to preferred embodiments described herein. It should be appreciated however that these embodiments are for

the purpose of illustrating the invention, and are not to be construed as limiting the scope of the invention as defined by the claims.

As used herein, the term "inflammatory bowel disease" includes ulcerative colitis and Crohn's disease.

5 As used herein, the term "non-absorbable antibiotic" means a compound having anti-bacterial activity, which, when delivered orally, results in less than 2 percent of the compound being excreted in the urine of the subject, in contrast to the sulfapyridine metabolite resulting from administration of sulfasalazine described above.


10 According to embodiments of the present invention, compounds are provided having the structure of Formula I:





where R<sup>1</sup> is a substituted or unsubstituted phenyl group, and where Z is selected such that a compound, Z-R<sup>1</sup>-NH<sub>2</sub>, formed by cleavage of the azo bond is a non-absorbable antibiotic. Preferably, the compound, Z-R<sup>1</sup>-NH<sub>2</sub>, is a metabolite formed by *in vivo* cleavage of the azo bond. R<sup>1</sup> is preferably an unsubstituted phenyl group. When R<sup>1</sup> is a substituted phenyl, it is preferably substituted with lower alkyl.


According to other embodiments of compounds of the present invention, Z is a moiety comprising carbonyl, sulfur, sulfinyl or sulfonyl; and a primary, secondary or tertiary amine. Preferably, Z is a moiety comprising sulfur, sulfinyl or sulfonyl; and a primary, secondary or tertiary amine.

According to yet other embodiments of compounds of the present invention, Z is -X-V, where X is carbonyl, sulfur, sulfinyl or sulfonyl; and V is a moiety comprising a primary, secondary or tertiary amine. Preferably, X is sulfur, sulfinyl or sulfonyl. More preferably, X is sulfonyl. In some embodiments, V is -NH-Y, where Y is selected from the group consisting of:






where  $\text{R}^2$  is hydrogen or hydroxy, and  $\text{R}^3$  is selected from the group consisting of:




5

In other embodiments, V is:



where  $\text{R}^4$  is substituted or unsubstituted phenyl, and  $\text{R}^5$  is selected from the group consisting of:




10

where  $\text{R}^6$  is a linear or branched alkyl having 1 to 10 carbon atoms. Preferably,  $\text{R}^4$  is unsubstituted phenyl. Preferably,  $\text{R}^6$  is a linear or branched alkyl having 1 to 6, 7 or 8 carbon atoms, and, more preferably,  $\text{R}^6$  is a linear or branched alkyl having 1 or 2 to 3, 4 or 5 carbon atoms.


15

According to preferred embodiments of the present invention, compounds are provided having the structure of Formula II:




20 where X is  $\text{---SO}_2\text{---}$  or  $\text{---CO---}$  and Y is:






where n is an integer from 1 to 10, is preferably an integer from 1 to 6, and is more preferably an integer from 1 to 3;



5


or




Compounds of the present invention may be utilized for the prophylaxis or treatment of various diseases including, but not limited to, intestinal diseases such as inflammatory bowel disease and traveler's diarrhea; liver diseases such as hepatic encephalopathy, liver failure, end-stage liver disease, cirrhosis, hepatitis, hepatic fibrosis, liver transplantation, and portal hypertension; and diseases that may be treated or prevented by administration of a non-absorbable antibiotic such as bacterial intestinal infections, pseudo membranous colitis, bacterial overgrowth, *Clostridium* difficile infection, salmonella enteritis, shigella infections, yersiniosis, *E. coli*, traveler's diarrhea, gram negative bacterial infections, gram positive bacterial infections, tuberculosis, cryptosporidiosis, and microsporidia infection.

The compounds of the present invention may also be utilized in diagnosis of constituents, conditions, or disease states in biological systems or specimens, as well as for diagnosis purposes in non-physiological systems. Furthermore, the compounds of the present invention may have application in prophylaxis or treatment of condition(s) or disease state(s) in plant systems. By way of example, the compounds of the present invention may have insecticidal, herbicidal, fungicidal, and/or pesticidal efficacy amenable to usage in various plant systems.


Compounds of the present invention preferably break down in the intestinal tract by azo reduction to provide 5-ASA and a non-absorbable antibiotic. For example, according to some embodiments of the present invention, the compounds of Formula II above may breakdown in the intestinal tract to form the metabolic products of Formulae III and IV:




and




where X is  $\text{—SO}_2\text{—}$  or  $\text{—CO—}$  and Y is:



where n is an integer from 1 to 10, is preferably an integer from 1 to 6, and is more preferably an integer from 1 to 3;



or



The metabolic product of Formula III preferably possesses anti-inflammatory activity, and more particularly may inhibit prostaglandin synthetase I and II. The metabolic product of Formula IV preferably possesses antibiotic activity and is a non-absorbable antibiotic. Accordingly, compounds of the present invention preferably provide both  
5 anti-inflammatory and antibiotic activity, and thus may be useful in treating various diseases, including, but not limited to, intestinal diseases, liver diseases, and diseases that may be treated or prevented by administration of a non-absorbable antibiotic.

In therapeutic usage, the present invention contemplates a method of treating an animal subject having or latently susceptible to such condition(s) or disease state(s)  
10 and in need of such treatment, comprising administering to such animal an effective amount of a compound of the present invention that is therapeutically effective for said condition or disease state. Subjects to be treated by the compounds of the present invention include both human and non-human animal (e.g., bird, dog, cat, cow, horse) subjects, and are preferably mammalian subjects, and most preferably human  
15 subjects.

Depending on the specific condition or disease state to be combatted, animal subjects may be administered compounds of the present invention at any suitable therapeutically effective and safe dosage, as may readily be determined within the skill of the art, and without undue experimentation. For example, compounds of the  
20 present invention may be administered at a dosage between about 0.1 and 100 mg/kg, preferably between about 5 and 90 mg/kg, and more preferably between about 10 and 80 mg/kg.

The compounds of the present invention may be administered per se as well as in the form of pharmaceutically acceptable esters, salts, and other physiologically  
25 functional derivatives thereof.

The present invention also contemplates pharmaceutical formulations, both for veterinary and for human medical use, which comprise as the active agent one or more compound(s) of the present invention. In such pharmaceutical and medicament formulations, the active agent preferably is utilized together with one or more  
30 pharmaceutically acceptable carrier(s) therefor and optionally any other therapeutic ingredients. The carrier(s) must be pharmaceutically acceptable in the sense of being compatible with the other ingredients of the formulation and are preferably not unduly deleterious to the recipient thereof. The active agent is provided in an amount

effective to achieve the desired pharmacological effect, as described above, and in a quantity appropriate to achieve the desired daily dose.

The formulations include those suitable for parenteral as well as non-parenteral administration, and specific administration modalities include oral, rectal, buccal, topical, nasal, ophthalmic, subcutaneous, intramuscular, intravenous, transdermal, intrathecal, intra-articular, intra-arterial, sub-arachnoid, bronchial, lymphatic, vaginal, and intra-uterine administration. Formulations suitable for oral and parenteral administration are preferred, with formulations suitable for oral administration most preferred.

When the active agent is utilized in a formulation comprising a liquid solution, the formulation advantageously may be administered orally or parenterally. When the active agent is employed in a liquid suspension formulation or as a powder in a biocompatible carrier formulation, the formulation may be advantageously administered orally, rectally, or bronchially.

When the active agent is utilized directly in the form of a powdered solid, the active agent may advantageously be administered orally. Alternatively, it may be administered bronchially, via nebulization of the powder in a carrier gas, to form a gaseous dispersion of the powder which is inspired by the patient from a breathing circuit comprising a suitable nebulizer device.

The formulations comprising the active agent of the present invention may conveniently be presented in unit dosage forms and may be prepared by any of the methods well known in the art of pharmacy. Such methods generally include the step of bringing the active ingredient(s) into association with a carrier which constitutes one or more accessory ingredients. Typically, the formulations are prepared by uniformly and intimately bringing the active ingredient(s) into association with a liquid carrier, a finely divided solid carrier, or both, and then, if necessary, shaping the product into dosage forms of the desired formulation.

Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets, tablets, or lozenges, each containing a predetermined amount of the active ingredient as a powder or granules; or a suspension in an aqueous liquor or a non-aqueous liquid, such as a syrup, an elixir, an emulsion, or a draught.

A tablet may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in

a suitable machine, with the active compound being in a free-flowing form such as a powder or granules which optionally is mixed with a binder, disintegrant, lubricant, inert diluent, surface active agent, or discharging agent. Molded tablets comprised of a mixture of the powdered active compound with a suitable carrier may be made by  
5 molding in a suitable machine.

A syrup may be made by adding the active compound to a concentrated aqueous solution of a sugar, for example sucrose, to which may also be added any accessory ingredient(s). Such accessory ingredient(s) may include, for example, flavorings, suitable preservatives, agents to retard crystallization of the sugar, and  
10 agents to increase the solubility of any other ingredient, such as a polyhydroxy alcohol, for example glycerol or sorbitol.

Formulations suitable for parenteral administration conveniently comprise a sterile aqueous preparation of the active compound, which preferably is isotonic with the blood of the recipient (e.g., physiological saline solution). Such formulations may  
15 include suspending agents and thickening agents or other microparticulate systems which are designed to target the compound to blood components or one or more organs. The formulations may be presented in unit-dose or multi-dose form.

Nasal spray formulations comprise purified aqueous solutions of the active compound with preservative agents and isotonic agents. Such formulations are  
20 preferably adjusted to a pH and isotonic state compatible with the nasal mucus membranes.

Formulations for rectal administration may be presented as a suppository with a suitable carrier such as cocoa butter, hydrogenated fats, or hydrogenated fatty carboxylic acid.

25 Ophthalmic formulations are prepared by a similar method to the nasal spray, except that the pH and isotonic factors are preferably adjusted to match that of the eye.

Topical formulations comprise the active compound dissolved or suspended in one or more media, such as mineral oil, petroleum, polyhydroxy alcohols, or other  
30 bases used for topical pharmaceutical formulations.

In addition to the aforementioned ingredients, the formulations of this invention may further include one or more accessory ingredient(s) selected from diluents, buffers, flavoring agents, disintegrants, surface active agents, thickeners, lubricants, preservatives (including antioxidants), and the like.

Accordingly, compounds according to the present invention may be utilized for the prophylaxis or treatment of various diseases, particularly intestinal diseases, and more particularly colonic inflammation diseases such as ulcerative colitis.

Compounds of the present invention may be made using known starting materials and reagents as will be understood by those skilled in the art. For example, compounds of the present invention may be synthesized as illustrated in Figures 1 and 2, where Y is as described above.

The present invention will now be described with reference to the following examples. It should be appreciated that these examples are for the purposes of illustrating aspects of the present invention, and do not limit the scope of the invention as defined by the claims.

### **EXAMPLES**

Melting points were taken on a Laboratory Devices Mel-Temp II capillary melting point apparatus and are uncorrected. <sup>1</sup>HNMR spectra were obtained on a Varian Unity 300 MHz spectrometer and chemical shifts (δ) are reported as parts per million (ppm) relative to internal standard tetramethylsilane. Infrared spectra were obtained with a Nicolet Impact 410. Ultraviolet and visible spectra were obtained with a Beckman DU 640i spectrophotometer. Fast atom bombardment (FAB) mass spectroscopy data was obtained by M-Scan Inc. All reagents were used as received from Aldrich Chemical Co.

#### **Examples 1 through 3**

#### **Synthesis of 5-[4-(2-Carboxy-Acetylsulfamoyl)-Phenylazo]-2-Hydroxy-Benzoic Acid**

##### **Example 1**

##### **3-(4-Nitro-Benzenesulfonylamino)-3-Oxo-Propionic Acid Ethyl Ester**

A 250-mL flask was charged with 4-nitrobenzenesulfonamide (10.8 g, 53.1 mmol) and sodium hydroxide (2.52 g, 63.1 mmol in 25 mL water). The solution was cooled in an ice bath and ethyl 3-chloro-3-oxobutyrates (6.40 mL, 50.0 mmol) was added dropwise. A precipitate formed, the suspension was allowed to warm to ambient temperature, and stirred for an additional 3 hours. The precipitate was

removed by vacuum filtration and the filtrate was extracted with ethyl acetate (3 x 30 mL). The extractions were combined and dried with MgSO<sub>4</sub>. The solution was then concentrated under reduced pressure and dried under vacuum. The crude product was a yellow solid with a 57% yield (9.05g): mp 97°C; <sup>1</sup>H NMR (DMSO-d<sub>6</sub>) δ 1.17 (3H, t), 3.32 (2H, s), 4.04 (2H, m) 7.71 (1H, s), 8.05 (1H, d, *J* = 9.0 Hz), 8.16 (1H, d, *J* = 8.1 Hz), 8.41 (2H, m); IR (KBr) 2979, 1758, 1690, 1527, 1326, 1207, 1095, 1013, 850, 656 cm<sup>-1</sup>; FAB-MS (NBA) *m/z* 317 (M+H)<sup>+</sup>.

### Example 2

#### 10      3-(4-Amino-Benzenesulfonylamino)-3-Oxo-Propionic Acid Ethyl Ester

To a 250-mL oven dried flask, 3-(4-nitro-benzenesulfonylamino)-3-oxo-propionic acid ethyl ester (2.00g, 6.32mmol), as obtained from the procedure of Example 1, was dissolved in absolute ethyl alcohol (100 mL). Palladium (10 wt. % on activated carbon, 0.20 g, 1.90 mmol) was added and a hydrogen environment was introduced into the flask. The mixture was then stirred at ambient temperature for 3 hours. The crude reaction mixture was filtered through Celite and ethyl alcohol was removed under reduced pressure. The crude product was dried under vacuum overnight resulting in a brown oil (93% yield, 1.68 g): <sup>1</sup>H NMR (DMSO-d<sub>6</sub>) δ 1.14 (2H, t), 3.28 (2H, s), 4.07 (2H, m), 6.57 (2H, m), 6.84 (1H, s), 7.44 (1H, d, *J* = 8.1 Hz), 7.52 (1H, d, *J* = 8.1 Hz); IR (KBr) 2979, 1746, 1639, 1583, 1370, 1295, 1164, 1026, 857, 669 cm<sup>-1</sup>; FAB-MS (NBA) *m/z* 287 (M+H)<sup>+</sup>.

### Example 3

#### 5-[4-(2-Carboxy-Acetylsulfamoyl)-Phenylazo]-2-Hydroxy-Benzoic Acid

25      3-(4-Amino-benzenesulfonylamino)-3-oxo-propionic acid ethyl ester (1.81 g, 6.32 mmol), as obtained from the procedure of Example 2, dissolved in an aqueous solution of HCl (5.5 mL, 36.5-38.0%) and water (3.5 mL) was placed in a 25-mL beaker and cooled to 0°C in an ice bath. When the solution stabilized at 0°C, sodium nitrite (0.44 g, 6.32 mmol) in water (3 mL) was added dropwise. The temperature was maintained at 0-5°C and the resulting diazonium salt solution was stirred for 15 minutes.

30      While the diazonium salt solution stirred, a 50-mL beaker fitted with a thermometer and pH probe (Orion model 420A with Orion semi-micro pH probe) was charged with salicylic acid, sodium salt (1.21 g, 7.59 mmol) dissolved in sodium

hydroxide (0.76 g, 19.0 mmol in 6 mL H<sub>2</sub>O). Using an ice bath, the salicylic acid solution was cooled to 17°C and the diazonium salt solution was slowly added dropwise. Throughout the addition, the pH was maintained at 13.2-13.3 with the addition of aqueous sodium hydroxide and the temperature was kept at 17-18°C with the addition of ice. After the addition was complete, the resulting dark red solution was allowed to warm to ambient temperature and stirring was continued for 1.5h. Using an ice bath, the solution was acidified to pH 2-3 with concentrated HCl (36.5 - 38.0%). A solid precipitated and was collected by vacuum filtration. The crude product was obtained as a red solid in 4% yield (116mg): mp 178°C; <sup>1</sup>H NMR (DMSO-d<sub>6</sub>) δ 3.28 (2H, s), 7.13 (1H, d, *J*= 9.0 Hz), 7.47 (1H, m), 7.76 (2H, d, *J*= 6.0 Hz), 7.98 (2H, d, *J*= 6.0 Hz), 8.35 (1H, s); IR (KBr) 3574, 1677, 1577, 1477, 1333, 1138, 1095, 838 cm<sup>-1</sup>; FAB-MS (NBA) *m/z* 408 (M+H)<sup>+</sup>, 430 (M+Na)<sup>+</sup>.

#### Examples 4 through 6

#### 15 **Synthesis of 5-[4-(4-Carboxy-Butyrylsulfamoyl)-Phenylazo]-2-Hydroxy-Benzoic Acid**

##### Example 4

#### **5-(4-Nitro-Benzenesulfonylamino)-5-Oxo-Pentanoic Acid Methyl Ester**

20 A 250-mL, 3-neck flask fitted with a condenser and stir bar was charged with 4-nitrobenzenesulfonamide (4.02 g, 19.8 mmol) and anhydrous pyridine (60 mL). The solution was heated to reflux using an oil bath and methyl 5-chloro-5-oxovalerate (3.28 mL, 23.7 mmol) was added dropwise. The solution refluxed for 3 hours, cooled to ambient temperature and continued stirring for 20 hours. The solution was acidified with HCl (50 mL, 36.5-38%) in water (150 mL) to pH 1-2 upon which a precipitate formed. The crude product was obtained by suction filtration as a brown solid (6.59 g): mp 114°C; <sup>1</sup>H NMR (DMSO-d<sub>6</sub>): δ 1.62 (2H, m), 2.19 (2H, m), 2.28 (2H, m), 3.52 (3H, s), 8.15 (2H, d, *J*= 9.0 Hz), 8.42 (2H, d, *J*= 9.0 Hz); IR (KBr) 3205, 1727, 1690, 1527, 1420, 1352, 1319, 1170, 1020, 838, 744 cm<sup>-1</sup>; negative FAB-MS (NBA) *m/z* 329 (M)<sup>-</sup>.



### Example 5

#### **5-(4-Amino-Benzenesulfonylamino)-5-Oxo-Pentanoic Acid Methyl Ester**

A 250-mL, 3-neck flask fitted with a condenser was charged with 5-(4-nitro-benzenesulfonylamino)-5-oxo-pentanoic acid methyl ester (6.00 g, 18.2 mmol), as  
5 obtained from the procedure of Example 4, dissolved in methanol (60 mL). A solution of ammonium chloride (5.64 g, 105 mmol) in water (60 mL) was added along with iron (3.55 g, 63.6 mmol, 325 mesh powder). The solution refluxed for 15 hours, cooled to ambient temperature, and was filtered through Celite. The solvent was removed under reduced pressure and methanol (200 mL) was added. The solution  
10 was filtered and concentrated under reduced pressure. The crude product was obtained as an orange solid in 91% yield (4.95g): mp >260°C; IR (KBr) 3117, 2823, 1746, 1596, 1395, 1157cm<sup>-1</sup>; FAB-MS (NBA) *m/z* 301 (M)<sup>+</sup>.

### Example 6

#### **5-[4-(4-Carboxy-Butyrylsulfoamoyl)-Phenylazo]-2-Hydroxy-Benzoic Acid**

5-(4-Amino-benzenesulfonylamino)-5-oxo-pentanoic acid methyl ester (4.00 g, 13.3 mmol), as obtained from the procedure of Example 5, dissolved in an aqueous solution of HCl (13 mL, 36.5-38%) and water (8 mL) was placed in a 100-mL beaker and cooled to 0°C in an ice bath. When the solution stabilized at 0°C, sodium nitrite  
20 (1.60 g, 39.9 mmol) in water (5 mL) was added dropwise. The temperature was maintained at 0-5°C and the resulting diazonium salt solution stirred for 20 minutes.

While the diazonium salt solution stirred, a 400-mL beaker fitted with a thermometer and pH probe (Orion model 420A with Orion semimicro pH probe) was charged with salicylic acid, sodium salt (2.56 g, 16.0 mmol) dissolved in sodium  
25 hydroxide (1.60 g, 39.9 mmol) in water (5 mL) and sodium carbonate (2.50 g, 23.6 mmol) in water (5 mL). Using an ice bath, the salicylic acid solution was cooled to 17°C and the diazonium salt solution was slowly added in 3-4 mL portions. Throughout the addition, the pH was maintained at 13.2-13.3 with the addition of aqueous sodium hydroxide and the temperature was kept at 17-18°C with the addition  
30 of ice. After the addition was complete, the resulting solution was allowed to warm to ambient temperature and stirring was continued for 1 hour. Using an ice bath, the solution was acidified to pH 1-2 with concentrated HCl (100 mL, 36.5-38%) in water (250 mL). A solid precipitated and was collected by suction filtration. The crude product was obtained as an orange solid in 6% yield (36.5 mg): mp 192°C; <sup>1</sup>H NMR

(DMSO- $d_6$ ):  $\delta$  1.62 (2H, m), 2.13 (2H, m), 2.28 (2H, m), 7.17 (1H, d,  $J$ = 7.8 Hz), 8.02 (3H, d,  $J$ = 6.0 Hz), 8.10 (2H, d,  $J$ = 7.8 Hz), 8.37 (1H, s); IR (KBr) 3092, 1677, 1441, 1169, 1143, 1070, 851, 659  $\text{cm}^{-1}$ ; FAB-MS (NBA)  $m/z$  434 (M) $^+$ .

5

### Examples 7 through 9

#### **Synthesis of 5-[4-(3-Carboxy-Propionylsulfamoyl)-Phenylazo]-2-Hydroxy-Benzoic Acid**

##### Example 7

10

#### **4-(4-Nitro-Benzenesulfonylamino)-4-Oxo-Butyric Acid Methyl Ester**

A 500-mL, 3-neck flask fitted with a condenser was charged with 4-nitrobenzenesulfonamide (8.03 g, 39.7 mmol) and anhydrous pyridine (150 mL). The solution was heated to reflux using an oil bath and methyl 4-chloro-4-oxobutyrate (5.90 mL, 47.9 mmol) was added dropwise. The solution refluxed for 17 hours, cooled to ambient temperature, and was further cooled to 0-5°C using an ice bath. The solution was acidified with conc. HCl (~50 mL, 36.5 - 38%) to pH 3 and poured into a beaker containing ~ 600 grams of ice upon which a precipitate formed. The crude product was obtained by suction filtration as a brown solid in 92% yield (11.5 g): mp 156°C;  $^1\text{H}$  NMR (DMSO- $d_6$ )  $\delta$  2.43 (2H, m), 2.50 (2H, m), 3.47 (3H, s), 8.14 (2H, d,  $J$ = 9.0 Hz), 8.41 (2H, d,  $J$ = 9.0 Hz); IR (KBr) 3211, 1739, 1706, 1533, 1434, 1348, 1162  $\text{cm}^{-1}$ ; FAB-MS (NBA)  $m/z$  317 (M+H) $^+$ .

20

##### Example 8

#### **4-(4-Amino-Benzenesulfonylamino)-4-Oxo-Butyric Acid Methyl Ester**

25

To a 500-mL, 2-neck flask fitted with an overhead stirrer and condenser, 4-(4-nitro-benzenesulfonylamino)-4-oxo-butyric acid methyl ester (10.0 g, 31.6 mmol), as obtained by the procedure of Example 7, was dissolved in methanol (100 mL). A solution of ammonium chloride (9.82 g, 184 mmol) in water (100 mL) was added along with iron (6.19 g, 11 mmol, 325 mesh powder). The solution was refluxed for 5.5 hours, cooled to ambient temperature and filtered through Celite. The solvent was removed under reduced pressure and methanol (400 mL) was added. The solution was filtered and concentrated under reduced pressure. The crude product was obtained as a brown solid (9.58 g): mp >260°C;  $^1\text{H}$  NMR (DMSO- $d_6$ )  $\delta$  2.38 (2H, m), 2.48 (2H, m), 3.46 (3H, s), 6.56 (2H, d,  $J$ = 8.4 Hz), 7.44 (2H, d,  $J$ = 8.4 Hz); IR (KBr)

30

3490, 3386, 3107, 1739, 1697, 1624, 1587, 1435, 1314, 1138, 1083, 980, 840  $\text{cm}^{-1}$   
FAB-MS (NBA)  $m/z$  287  $(M+H)^+$ .

### Example 9

#### 5      5-[4-(3-Carboxy-Propionylsulfamoyl)-Phenylazo]-2-Hydroxy-Benzoic Acid

4-(4-Amino-benzenesulfonylamino)-4-oxo-butyric acid methyl ester (11.5 g, 40.2 mmol), as prepared from the procedure of Example 8, dissolved in an aqueous solution of HCl (35 mL, 36.5 - 38.0%) and water (25 mL) was placed in a 500-mL beaker and cooled to 0°C in an ice bath. When the solution stabilized at 0°C, sodium  
10      nitrite (2.77 g, 40.2 mmol) in water (15 mL) was added slowly in 5 mL portions. The temperature was maintained at 0-5°C and the resulting diazonium salt solution was stirred for 15 minutes.

While the diazonium salt solution stirred, a 1L beaker fitted with a thermometer and pH probe (Orion model 420A with Orion semimicro pH probe) was  
15      charged with salicylic acid, sodium salt (6.44 g, 40.2 mmol) dissolved in sodium hydroxide (4.83 g, 121 mmol in 15 mL  $\text{H}_2\text{O}$ ) and sodium carbonate (7.54 g, 71.2 mmol in 15 mL  $\text{H}_2\text{O}$ ). Using an ice bath, the salicylic acid solution was cooled to 17°C and the diazonium salt solution was slowly added in 20 mL portions. Throughout the addition, the pH was maintained at 13.2 - 13.3 with the addition of aqueous sodium  
20      hydroxide and the temperature was kept at 17-18°C with the addition of ice. After the addition was complete, the resulting dark red solution was allowed to warm to ambient temperature and stirring was continued for an additional 30 minutes. Using an ice bath, the solution was acidified to pH 2-3 with concentrated HCl (300 mL, 36.5 - 38.0%) in water (500 mL). A solid precipitated and was collected by suction  
25      filtration. The crude product was obtained as an orange solid in 36% yield (6.24 g): mp 192°C,  $^1\text{H}$  NMR ( $\text{DMSO}-d_6$ )  $\delta$  2.37 (2H, m), 2.46 (2H, m), 7.14 (1H, d,  $J=9.0$  Hz), 7.97 (1H, d,  $J=8.4$  Hz), 8.00 (2H, d,  $J=8.4$  Hz), 8.06 (2H, d,  $J=8.4$  Hz), 8.34 (1H, s); IR (KBr) 3596, 3536, 3178, 1713, 1680, 1573, 1448, 1334, 1182, 1123, 1063, 851, 791, 612  $\text{cm}^{-1}$ ; UV-Vis (MeOH)  $\lambda_{\text{max}} = 353$  nm,  $\epsilon = 23,400$   $\text{mol}^{-1} \text{cm}^{-1}$  L; FAB-  
30      MS (NBA)  $m/z$  420  $(M)^+$ .

### Example 10

#### Metabolism of 5-[4-(3-Carboxy-Propionylsulfamoyl)-Phenylazo]-2-Hydroxy-Benzoic Acid (1) Following Oral Delivery

5 5-[4-(3-Carboxy-propionylsulfamoyl)-phenylazo]-2-hydroxy-benzoic acid (1), a compound of the present invention, and sulfasalazine (used as a control; not part of the present invention) were orally dosed to rats. The degradation and the generation of their metabolites after the oral dosing were measured to be able to confirm that (1) undergoes bacterial azo reduction and yields its metabolites, 5-aminosalicylic acid (5-ASA) and C4 sulfanamide.

10 This experiment was performed to confirm that (1) undergoes a bacterial reduction process and yields its metabolites in *in-vivo* metabolism. The quantification of its metabolites was also carried out. Sulfasalazine was used as a control since the same azo bond cleavage by bacteria occurs with it, which results in 5-aminosalicylic acid and sulfapyridine as its metabolites. (1) was degraded and its metabolites were  
15 produced as expected.

A total of 7 rats were used for the experiment and methylcellulose was used as a vehicle. The dosage amount was 100 mg/kg per rat. Three rats were dosed with (1) and the other three rats were dosed with sulfasalazine. One rat was used as a control and dosed with methylcellulose. Both urine and feces were collected over 2 days and  
20 analyzed by HPLC.

Urine was collected each day and 300  $\mu$ L of aliquot from each sample was centrifuged for 10 minutes at 5000 g. 80  $\mu$ L of supernatant was injected for analysis. Feces was also collected each day and homogenized with a 1:1 mixture of water and acetonitrile. This mixture was then centrifuged for 20 minutes at 5000 g. 80  $\mu$ L of  
25 supernatant was injected for analysis.

A Waters 2690 HPLC was used for sample analysis as follows:

Mobile phase programming: Gradient

Mobile phase:

A=Water + 0.1 % TFA

B= Acetonitrile + 0.1 % TFA

30 Flow rate:

1 mL/min.

Column:

Phenomenex Max RP, 80 Å, 4.6 mm x 250 mm

PDA settings:

Collected spectrum: 210-400nm

Extracted chromatogram: 280 and/or other

Run time/sample:

Approximately 50 min.


| Time | Flow<br>(mL/minute) | % Mobile<br>Phase A | % Mobile<br>Phase B |
|------|---------------------|---------------------|---------------------|
| -    | 1                   | 100                 | 0                   |
| 40   | 1                   | 50                  | 50                  |
| 43   | 1                   | 5                   | 95                  |
| 44   | 1                   | 95                  | 5                   |
| 50   | 1                   | 95                  | 5                   |

For urine, only a very small amount of (1) was detected from 2 days collection and none of its metabolites were detected. For feces, (1) was not detected, but acetylated 5-ASA and C4 sulfanamide were detected from day 1 collection. No compounds were detected from day 2 collection. Sulfasalazine was also degraded, but only one rat showed the generation of sulfapyridine. Most rats showed acetylated 5-ASA from day 1 collection. No compounds were detected from day 2 collection. The results from this study show that both (1) and sulfasalazine undergo azo reduction.


The foregoing is illustrative of the present invention, and is not to be construed as limiting thereof. The invention is defined by the following claims, with equivalents of the claims to be included therein.

THAT WHICH IS CLAIMED IS:


1. A compound of the formula:




where X is  $-\text{SO}_2-$  or  $-\text{CO}-$  and Y is:



- 5 where n is an integer from 1 to 3;




or



- 10 or the esters or pharmacologically acceptable salts thereof.

2. The compound according to Claim 1, wherein X is  $-\text{SO}_2-$  and Y is:




where n is an integer from 1 to 3.

3. The compound according to Claim 1, 5-[4-(2-carboxy-acetylsulfamoyl)-phenylazo]-2-hydroxy-benzoic acid.


4. The compound according to Claim 1, 5-[4-(4-carboxy-butylsulfoamoyl)-phenylazo]-2-hydroxy-benzoic acid.

5. The compound according to Claim 1, 5-[4-(3-carboxy-propionylsulfamoyl)-phenylazo]-2-hydroxy-benzoic acid.


6. A pharmaceutical composition for the treatment of an intestinal disease in subjects in need of such treatment, comprising an amount effective to treat the intestinal bowel disease of a compound of the formula:



5 where X is  $\text{—SO}_2\text{—}$  or  $\text{—CO—}$  and Y is:




where n is an integer from 1 to 3;




10

or



or an ester or pharmacologically acceptable salt thereof, in admixture with a solid or liquid pharmaceutical diluent or carrier.

7. The pharmaceutical composition according to Claim 6, wherein X is  $\text{—SO}_2\text{—}$  and Y is:




where n is an integer from 1 to 3.

8. The pharmaceutical composition according to Claim 6, wherein the compound is 5-[4-(2-carboxy-acetylsulfamoyl)-phenylazo]-2-hydroxy-benzoic acid.


9. The pharmaceutical composition according to Claim 6, wherein the compound is 5-[4-(4-carboxy-butyrylsulfoamoyl)-phenylazo]-2-hydroxy-benzoic acid.

10. The pharmaceutical composition according to Claim 6, wherein the compound is 5-[4-(3-carboxy-propionylsulfamoyl)-phenylazo]-2-hydroxy-benzoic acid.


11. A method of treating an intestinal disease in a subject in need of such treatment, said method comprising administering to the subject an amount effective to treat the intestinal disease of a compound having the following formula:



5 where X is  $\text{---SO}_2\text{---}$  or  $\text{---CO---}$  and Y is:




where n is an integer from 1 to 3;



or


10





or an ester or pharmacologically acceptable salt thereof.

12. The method according to Claim 11, wherein X is  $\text{—SO}_2\text{—}$  and Y is:



where n is an integer from 1 to 3.

13. The method according to Claim 11, wherein the compound is 5-[4-(2-carboxy-acetylsulfamoyl)-phenylazo]-2-hydroxy-benzoic acid.

14. The method according to Claim 11, wherein the compound is 5-[4-(4-carboxy-butyrylsulfoamoyl)-phenylazo]-2-hydroxy-benzoic acid.


15. The method according to Claim 11, wherein the compound is 5-[4-(3-carboxy-propionylsulfamoyl)-phenylazo]-2-hydroxy-benzoic acid.

16. The method according to Claim 11, wherein the intestinal disease is Crohn's disease.


17. The method according to Claim 11, wherein the intestinal disease is ulcerative colitis.

18. The method according to Claim 11, wherein the intestinal disease is traveler's diarrhea.


19. A pharmaceutical composition for the treatment of a liver disease in subjects in need of such treatment, comprising an amount effective to treat the liver disease of a compound of the formula:



5 where X is  $\text{—SO}_2\text{—}$  or  $\text{—CO—}$  and Y is:




where n is an integer from 1 to 3;




10

or



or an ester or pharmacologically acceptable salt thereof, in admixture with a solid or liquid pharmaceutical diluent or carrier.

20. The pharmaceutical composition according to Claim 19, wherein X is  $\text{—SO}_2\text{—}$  and Y is:



where n is an integer from 1 to 3.


21. The pharmaceutical composition according to Claim 19, wherein the compound is 5-[4-(2-carboxy-acetylsulfamoyl)-phenylazo]-2-hydroxy-benzoic acid.

22. The pharmaceutical composition according to Claim 19, wherein the


compound is 5-[4-(4-carboxy-butyrylsulfoamoyl)-phenylazo]-2-hydroxy-benzoic acid.

23. The pharmaceutical composition according to Claim 19, wherein the compound is 5-[4-(3-carboxy-propionylsulfamoyl)-phenylazo]-2-hydroxy-benzoic acid.


24. A method of treating a liver disease in a subject in need of such treatment, said method comprising administering to the subject an amount effective to treat the liver disease of a compound having the following formula:



5 where X is  $\text{---SO}_2\text{---}$  or  $\text{---CO---}$  and Y is:




where n is an integer from 1 to 3;




10

or



or an ester or pharmacologically acceptable salt thereof.

25. The method according to Claim 24, wherein X is  $\text{---SO}_2\text{---}$  and Y is:



where n is an integer from 1 to 3.


26. The method according to Claim 24, wherein the compound is 5-[4-(2-carboxy-acetylsulfamoyl)-phenylazo]-2-hydroxy-benzoic acid.

27. The method according to Claim 24, wherein the compound is 5-[4-(4-carboxy-butyrylsulfoamoyl)-phenylazo]-2-hydroxy-benzoic acid.

28. The method according to Claim 24, wherein the compound is 5-[4-(3-carboxy-propionylsulfamoyl)-phenylazo]-2-hydroxy-benzoic acid.

29. The method according to Claim 24, wherein the liver disease is hepatic encephalopathy.

30. A compound of the formula:



where  $\text{R}^1$  is a substituted or unsubstituted phenyl group, and where Z is selected such that a compound,  $\text{Z-R}^1\text{-NH}_2$ , formed by cleavage of the azo bond is a non-absorbable antibiotic;

or an ester or pharmacologically acceptable salt of the compound of Formula I.




31. The compound according to Claim 30, wherein Z is a moiety comprising carbonyl, sulfur, sulfinyl or sulfonyl; and a primary, secondary or tertiary amine.

32. The compound according to Claim 30, wherein Z is a moiety comprising sulfur, sulfinyl or sulfonyl; and a primary, secondary or tertiary amine.


33. The compound according to Claim 30, wherein Z is  $-X-V$ , where X is carbonyl, sulfur, sulfinyl or sulfonyl; and V is a moiety comprising a primary, secondary or tertiary amine.

34. The compound according to Claim 33, wherein X is sulfur, sulfinyl or sulfonyl.


35. The compound according to Claim 33, wherein V is  $-NH-Y$ , where Y is selected from the group consisting of:




where  $R^2$  is hydrogen or hydroxy, and  $R^3$  is selected from the group consisting of:



36. The compound according to Claim 33, wherein V is:



where  $R^4$  is substituted or unsubstituted phenyl, and  $R^5$  is selected from the group consisting of:




where  $R^6$  is a linear or branched alkyl having 1 to 10 carbon atoms.

37. The compound according to Claim 36, wherein  $R^4$  is an unsubstituted phenyl group.

38. The compound according to Claim 36, wherein  $R^6$  is a linear or branched alkyl having 1 to 4 carbon atoms.

39. A pharmaceutical composition for the treatment of a disease that is treatable by a non-absorbable antibiotic in subjects in need of such treatment, comprising an amount effective to treat the disease of a compound of the formula:



5 where  $R^1$  is a substituted or unsubstituted phenyl group, and where Z is selected such that a compound,  $Z-R^1-NH_2$ , formed by cleavage of the azo bond is a non-absorbable antibiotic; or an ester or pharmacologically acceptable salt of the compound of Formula I, in admixture with a solid or liquid pharmaceutical diluent or carrier.

10




40. The pharmaceutical composition according to Claim 39, wherein Z is a moiety comprising carbonyl, sulfur, sulfinyl or sulfonyl; and a primary, secondary or tertiary amine.

41. The pharmaceutical composition according to Claim 39, wherein Z is a moiety comprising sulfur, sulfinyl or sulfonyl; and a primary, secondary or tertiary amine.


42. The pharmaceutical composition according to Claim 39, wherein Z is -X-V, where X is carbonyl, sulfur, sulfinyl or sulfonyl; and V is a moiety comprising a primary, secondary or tertiary amine.

43. The pharmaceutical composition according to Claim 42, wherein X is sulfur, sulfinyl or sulfonyl.


44. The pharmaceutical composition according to Claim 42, wherein V is -NH-Y, where Y is selected from the group consisting of:




where  $R^2$  is hydrogen or hydroxy, and  $R^3$  is selected from the group consisting of:



45. The pharmaceutical composition according to Claim 42, wherein V is:



where  $R^4$  is substituted or unsubstituted phenyl, and  $R^5$  is selected from the group consisting of:




where  $R^6$  is a linear or branched alkyl having 1 to 10 carbon atoms.

46. The pharmaceutical composition according to Claim 45, wherein  $R^4$  is an unsubstituted phenyl group.

47. The pharmaceutical composition according to Claim 45, wherein  $R^6$  is a linear or branched alkyl having 1 to 4 carbon atoms.

48. A method of treating a disease treatable by a non-absorbable antibiotic in a subject in need of such treatment, said method comprising administering to the subject an amount effective to treat the disease of a compound having the following formula:



where  $R^1$  is a substituted or unsubstituted phenyl group, and where Z is selected such that a compound,  $Z-R^1-NH_2$ , formed by cleavage of the azo bond is a non-absorbable antibiotic;

or an ester or pharmacologically acceptable salt of the compound of Formula

10 I.

49. The method according to Claim 48, wherein Z is a moiety comprising carbonyl, sulfur, sulfinyl or sulfonyl; and a primary, secondary or tertiary amine.




50. The method according to Claim 48, wherein Z is a moiety comprising sulfur, sulfinyl or sulfonyl; and a primary, secondary or tertiary amine.

51. The method according to Claim 48, wherein Z is  $-X-V$ , where X is carbonyl, sulfur, sulfinyl or sulfonyl; and V is a moiety comprising a primary, secondary or tertiary amine.




52. The method according to Claim 51, wherein X is sulfur, sulfinyl or sulfonyl.


53. The method according to Claim 51, wherein V is -NH-Y, where Y is selected from the group consisting of:




where  $R^2$  is hydrogen or hydroxy, and  $R^3$  is selected from the group consisting of:



54. The method according to Claim 51, wherein V is:




where  $R^4$  is substituted or unsubstituted phenyl, and  $R^5$  is selected from the group consisting of:




where  $R^6$  is a linear or branched alkyl having 1 to 10 carbon atoms.

55. The method according to Claim 54, wherein  $R^4$  is an unsubstituted phenyl group.

56. The method according to Claim 54, wherein R<sup>6</sup> is a linear or branched alkyl having 1 to 4 carbon atoms.
57. The method according to Claim 48, wherein the disease is Crohn's disease.
58. The method according to Claim 48, wherein the disease is ulcerative colitis.
59. The method according to Claim 48, wherein the disease is traveler's diarrhea.
60. The method according to Claim 48, wherein the disease is hepatic encephalopathy.



**FIG. 1.**



**FIG. 2.**

## INTERNATIONAL SEARCH REPORT

In: ☐ National Application No

PCT/US 01/41910

A. CLASSIFICATION OF SUBJECT MATTER  
 IPC 7 C07C311/51 C07C311/41 A61K31/195

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07C A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

CHEM ABS Data, BEILSTEIN Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages  | Relevant to claim No.      |
|------------|---|----------------------------|
| A          | US 4 412 992 A (R.P.K CHAN)<br>1 November 1983 (1983-11-01)<br>cited in the application<br>the whole document<br>----                                   | 1,6,11,<br>30,39,<br>48,58 |
| A          | I. KIMURA ET AL: DRUG RES. ,<br>vol. 48(II), no. 11, 1998, pages<br>1091-1096, XP000926669<br>page 1092, introduction; page 1095,<br>discussion<br>---- | 1,6,11,<br>30,39,<br>48,58 |
| A          | E. HACKMANN ET AL: BOLL. CHIM. FARM.,<br>vol. 114, no. 9, 1975, pages 501-508,<br>XP000926670<br>page 501, summary; table I<br>-----<br>-/--            | 1,6,11,<br>30,39,<br>48,58 |

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

## \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*Z\* document member of the same patent family

Date of the actual completion of the international search

17 December 2001

Date of mailing of the international search report

27/12/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax: (+31-70) 340-3016

Authorized officer

Van Amsterdam, L

## INTERNATIONAL SEARCH REPORT

Int. Patent Application No.

PCT/US 01/41910

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages  | Relevant to claim No. |
|------------|---|-----------------------|
| A          | US 2 270 676 A (R. BEHNISCH ET AL)<br>20 January 1942 (1942-01-20)<br>page 1, column 1, lines 1-25; page 2,<br>column 1, lines 52-63<br>----- | 1,30                  |
| A          | S.A.A. OSMAN ET AL: J. PHARM. SCI.,<br>vol. 72, no. 1, 1983, pages 68-71,<br>XP000971918<br>table II, compound II<br>-----                    | 1,30                  |
| A          | E. FROMMEL ET AL: HELV. PHYSIOL. ACTA,<br>vol. 3, 1945, pages 261-268, XP000926724<br>the whole document<br>-----                             | 1,30                  |
| A          | B.C. JAIN ET AL: J. INDIAN CHEM. SOC.,<br>vol. 24, 1947, pages 173-176, XP002037442<br>page 175, compound V<br>-----                          | 1,30                  |

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

## Continuation of Box I.2

Present claims 30-38 relate to compounds defined by reference to a desirable characteristic or property, namely the ability to form, upon cleavage of the azo bond present in these compounds, a non-absorbable antibiotic.

The claims cover all compounds having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for only a very limited number of such compounds. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the compounds by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the compounds claimed in claims 35-38 and 1-5.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 01/41910

| Patent document<br>cited in search report |   | Publication<br>date | Patent family<br>member(s) | Publication<br>date |
|---|---|---------------------|----------------------------|---------------------|
| US 4412992                                | A | 01-11-1983          | DE 3128819 A1              | 15-04-1982          |
|   |   |                     | FR 2493312 A1              | 07-05-1982          |
|   |   |                     | GB 2080796 A ,B            | 10-02-1982          |
|   |   |                     | HK 31885 A                 | 03-05-1985          |
|   |   |                     | IT 1138450 B               | 17-09-1986          |
|   |   |                     | JP 1433303 C               | 07-04-1988          |
|   |   |                     | JP 57053449 A              | 30-03-1982          |
|   |   |                     | JP 62025656 B              | 04-06-1987          |
|   |   |                     | MY 2986 A                  | 31-12-1986          |
|   |   |                     | SG 6885 G                  | 14-06-1985          |
| <hr/>                                     |   |                     |                            |                     |
| US 2270676                                | A | 20-01-1942          | NONE                       |                     |
| <hr/>                                     |   |                     |                            |                     |

Form PCT/SA/210 (patent family annex) (July 1992)



**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☒ **BLACK BORDERS**

☒ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**

☐ **FADED TEXT OR DRAWING**

☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**

☐ **SKEWED/SLANTED IMAGES**

☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**

☐ **GRAY SCALE DOCUMENTS**

☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**

☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**

☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**

**THIS PAGE BLANK (USPTO)**